The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

South Korean pharmaceutical and biotech companies are on track to exceed 10 trillion won ($7.5 billion) in licensing revenues ...

Eli Lilly’s total deal value with Rznomics could exceed $1.3 billion, plus royalties. Rznomics will lead early-stage research; Lilly to handle development and sales. Memorial Day Special ...

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal focused on treating hearing loss. The centerpiece of the agreement is ...

Concurrently, Korea-based OliX Pharmaceuticals Inc. announced a global licensing agreement with Eli Lilly for the development and commercialization of OliX's OLX75016, a Phase 1 candidate ...

Eli Lilly has begun the week with a bang ... looking at genomic variants linked to MASH and other liver diseases. The Korean biotech is running a phase 1 trial of the candidate in healthy ...

Eli Lilly chairman and Chief Executive Officer David ... Health News // 2 days ago FDA issues norovirus warning on frozen oysters from South Korea May 23 (UPI) -- The U.S. Food and Drug ...

Eli Lilly expands its partnership with AdvanCell to advance targeted alpha therapies using Pb-212 technology for cancer treatment. Lilly inks a global licensing deal with OliX for OLX75016, a ...